Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma

Annals of Oncology

Volumn 9, Issue SUPPL. 1, 1998, Pages

  Slavin, S ^a   Nagler, A ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Graft versus lymphoma; Immunotherapy; Interferon ; Interleukin 2; Minimal residual disease

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2; THIOTEPA;

CANCER IMMUNOTHERAPY; CANCER RECURRENCE; DRUG SAFETY; FATIGUE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOMA; NEUROTOXICITY; PRIORITY JOURNAL; RASH; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0031896995     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/9.suppl_1.S31     Document Type: Review

References (71)

1. Chopra R, Goldstone AH, Pearce R et al. Autologous vs. allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case controlled analysis of the European Bone Marrow Transplant Group Registry Data. J Clin Oncol 1992; 10: 1690-5.
2. Slavin S, Nagler A. New developments in bone marrow transplantation. Curr Opin Oncol 1991; 254-71.
3. Horowitz MM, Gale RP, Sondel P, Graft vs. leukemia reactions after hone marrow transplantation. Blood 1990; 75: 555-62.
4. Goldman JM, Gale RP, Horowitz MM. Bone marrow transplantation of chronic myclogenous leukemia in chronic phase: Increased risk of relapse associated with T cell depletion. Ann Intern Med 1988; 108: 806- 14.
5. Antin HJ. Graft vs. leukemia: No longer an epiphenomenon. Blood 1993; 82: 2273-7.
6. Philips GL, Herzig RH, Lazarus HM et al. High-dose chemotherapy, fractionated total body irradiation and allogeneic marrow transplantation for malignant lymphoma. J Clin Oncol 1986; 4: 480.
7. Ernst P, Devol E. Allogeneic hone marrow transplantation in malignant lymphoma. The European bone marrow transplant group exericse. Proceedings of the 4th International Conference Lymphoma. Lugano, Switzerland, June 9-12 1990; 35 (Ahstr).
8. Jones RJ, Ambinder RF, Piantadose S, Santos GW. Evidence of a graft vs. lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649.
9. Slavin S, Ackerstein A, Weiss L. Adoptive immunotherapy in conjunction with hone marrow transplantation amplification of natural host defence mechanisms against cancer by recombinant IL-2. Nat Immun Cell Growth Regul 1988; 7: 180-4.
10. Nagler A, Ackerstein A Or R, Naparstek E, Slavin S. Immunotherapy with recombinant human interleukin (rIL-2) and recombinant alpha-interferon in lymphoma patients post autologous marrow or stem cell transplantation. Blood 1997; 89 (11): 3951-9.
11. Nagler A, Morecki S, Ackerstein A et al. Experimental and Clinical Cellular Immunotherapy in Bone Marrow Transplantation. In Morstyn G, Sheridan W (eds): Cell Therapy: Stem Cell Transplantation. Gene Therapy, and Cellular Immunotherapy. New York: Cambridge University Press 1996; 29: 527-19.
12. Slavin S, Naparstek E, Or R et al. Immune adjuvant therapy alter high-dose therapy. In Armitage JO. Amman KH (eds): High-Dose Cancer Therapy. Baltimore, MD: William & Wilkins 1996; 7: 120- 30.
13. Linch DC, Knott LJ. Thomas RM et al. T cell regeneration after allogeneic and autologous bone marrow transplantation. Br J Haematol 1983; 53: 451-8 .
14. Slavin S, Strober S. Spontaneous murine B-cell leukemia. Nature 1978; 272: 624-6.
15. Slajvin S, Weiss I, Morecki S et al. Ultrastructural, cell membrane and cytogenetic characteristics of B cell leukemia (bel-1), a murine model of chronic lymphocytic leukemia. Cancer Res 1981; 41: 4162-6.
16. Ackerstein A, Kedar E, Slavin S, Use of recombinant human interleukin-2 in conjunction with sygeneic bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. Blood 1991: 78: 1212-5.
17. Robb RJ, Green WC. Direct demonstration of the identity of T cell growth factor binding protein and the TAC antigen. J Exp Med 1983; 158: 1332.
18. Waldman. TA. The structure, function and expression of IL-2 receptor on normal and malignant lymphocytes. Science. 1986; 232: 727.
19. Lowenthal JW, Zubler RH, Nabholz M, Macdonald HR. Similarities between interleukin-2 receptors number and affinity on activated B and T lymphocytes. Nature 1985; 315: 669.
20. Rosenberg SA, Lotze MT, Muul LM. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 and high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889.
21. Morecki S, Revel-Vilk S, Nabel C et al. Immunological evaluation of patients with hematological malignancies receiving ambulatory cylokine-mediated immunotherapy with recombinant human interferon-α-2a and interleukin-2. Cancer Immunol Immunother 1992; 35: 401-41.
22. Morecki S, Nagler A, Puyesky Y et al. Effect of various cytokine combinations on induction of non-MHC restricted cytotoxicity. Lymphok Cytok Res 1993; 12(3): 159-65.
23. Dutcher JP, Wiernik PH. The role of recombinant interleukin-2 therapy for hematologic malignancies. Semin Oncol 1993; 20: 33.
24. Duggan, DB, Santarell MT. Zamkoff K et al. A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of cancer and leukemia group B. Br J Immunother 1992; 12: 115.
25. Bernstein ZP, Vaikus L, Friedman N et al. Interleukin-2 lymphokine-activaled killer cell therapy of non-Hodgkin's lymphoma and Hodgkin's disease. J Immunother 1991; 10: 141.
26. Lim SH, Worman CP, Callahan T et al. Continuous intravenous infusion of high-dose recombinant interleukin-2 for advanced lymphmas: A phase II study. Leuk Res 1991; 15: 435.
27. Weber JS, Yang JC, Topalian SL et al. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. J Clin Oncol 1992; 10: 33.
28. Gisselbrecht C, Maraninchi D, Pico JL et al. Interleukin-2 treatment in lymphoma: A phase II multicenler study. Blood 1994; 83: 2081.
29. Fefer A, Benyunes M, Higuchi C et al. Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies. Acta Hematol 1993; 89 (Suppl 1): 2.
30. Fefer A, Benyunes M, Massamoto C et al. Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 1993; 20: 41.
31. Talpaz M, Kanatarjian HM, McCredie K, Trujilo JM. Hematologic remission and cytogenetic improvement induced by recombinant human interferon-α-A in chronic myclogenous leukemia. N Engl J Med 1986; 314: 1065.
32. Quesada JR, Reuben J, Manning JT et al. α-interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984; 310: 15.
33. Brunda MJ, Rosenbaum D. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons. Cancer Res 1984; 44: 597.
34. Nagler A, Lanier LL, Phillips JH. The effects of interleukin-4 on human natural killer cells. A potent regulator of interleukin-2 activation and proliferation. J Immunol 1988; 141: 2349.
35. Brunda MJ, Bellantoni D, Sulich V. In vivo antitumor activity of combinations of interferon-λ and inlerleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells, Int J Cancer 1987; 40: 365.
36. Igio M, Sakurai M, Tamura T, Saijo N. In vivo antitumor activity of multiple injections of recombinant interleukin-2. alone and in combination with three different types of recombinant Interferon, on various syngeneic murine tumors. Cancer Res 1988; 48: 260.
37. Hauch M, Gazzola MV, Small T, Bordignon C. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990; 75: 2250.
38. Pawalec G, Schneider E, Ehninger G, Rehbein A. Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukemia after in vivo treatment with interferon-α (Wellferon). Cancer Immunol Immunother 1989; 29: 63.
39. Rosenberg SA, Lotze MT, Yang JC et al. Combination therapy with interleukin-2 and α-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989; 7: 1863.
40. Hirsh M, Lipton A, Harvey H et al. Phase I study of interleukin-2 and interferon-2-2A as outpatient therapy for patients with advanced malignancy. J Clin Oncol 1990; 8: 1657.
41. Krigel RL, Padavic-Shaller KA, Rudolph AR et al. A phase I study of recombinant interleukin-2 plus recombinant β-interferon. Cancer Res 1988; 48: 3875.
42. Lee KH, Talpaz M, Rothberg JM et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon-α-2A in cancer patients: A phase I study. J Clin Oncol 1989; 7: 1726.
43. Gilewski TA, Richards JM. Biologic response modifiers in non-Hodgkin's lymphomas. Semin Oncol 1990; 17: 74.
44. Quesada JR, Talpaz M, Rios A et al. Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 1986; 4: 234.
45. McLaughlin P. The role of interferon in the therapy of low-grade lymphoma. Leuk Lymph 1993; 10 (Suppl): 17.
46. Smalley RV, Andersen JW, Hawkins NJ et al. Interferon-α combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1336.
47. Nagler A, Ackerstein A, Barak V, Slavin S. Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-α-2A. J Hematother 1994; 3: 75-82.
48. Nagler A, Ackerstein A, Or R et al. Pulse therapy with interleukin-2 (rIL-2) followed by interferon-α maintenance immunotherapy for malignant lymphoma (ML) patients after autologous peripheral blood stem cell transplantation. Blood 1997; 90: 382a.
49. Ringden O. Horowitz MM for the advisory comittee of the international BMT registry. Graft vs. leukemia reactions in humans. Transplant Proc 1989; 21: 2989-92.
50. Weiss L, Reich S, Slavin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I. Treatment of murine leukemia in conjunction with allogeneic bone marrow tansplantation and IL-2 activated cell-mediated immunotherapy. Cancer Invest 1992; 10: 19-26.
51. Slavin S, Ackerstein A, Weiss L et al. Immmunotherapy of minimal reisdual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest 1992; 10: 221-7.
52. Slavin S, Or R, Naparstek E et al. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood 1988; 72 (Suppl 1): 407a.
53. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23: 1553-62.
54. Kolb HJ, Schattenberg A, Goldman JM, Graft vs. leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041 50.
55. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leuekmia relapse post allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
56. Collins RH, Shpilber O, Dobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-44.
57. Slavin S, Weiss L, Morecki S, Weigensberg M. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother 1981; 11: 155-8.
58. Weiss L, Weigensberg M, Morecki S et al. Characterization of effector cells of graft vs. leukemia (GVL) following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia (bcl-1). Cancer Immunol Immunother 1990; 31: 236-42.
59. Weiss L, Lubin I, Factorowich Y et al. Effective graft vs. leukemia effects independent of graft vs. host disease after T-cell depleted allogeneic bone marrow transplantation in a murine model of B-cell leukemia/lymphoma. Role of cell therapy and rIL-2. J Immunol 1994; 153 (6): 2562-7.
60. Slavin S, Ackerstein A, Kedar E et al. Induction of cell-mediated IL-2 activated antitumor responses in conjunction with autologous and allogeneic bone marrow transplantation. Transplant Proc 1991; 23: 802-3.
61. Vourka-Karussis U, Karussis D, Ackerstein A, Slavin S. Enhancement of graft vs. leukemia effect (GVL) with recombinant human interleukin-2 (rIL-2) following bone marrow transplantation in a murine model for acute myeloid leukemia in SJL/J mice. Exp Hematol 1995; 23: 201-8.
62. Slavin S, Or R, Naparstek E et al. Eradication of minimal residual disease (MRD) following autologous (ABMT) and allogeneic bone marrow transplantation (BMT) by cytokine-mediated immunotherapy (CMI) and cell-mediated cytokine-activated immunotherapy (CCI) in experimental animals and man. Blood 1992; 80: 535a.
63. Johnson BD, Drobyski WR, Truitt RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantationprovides an antileukemia reaction without graft vs. host disease. Bone Marrow Transplant 1993; 11: 329-36.
64. Or R, Nagler A, Ackerstein A et al. Allogeneic cell-mediated cytokine-activated immunotherapy of non-Hodgkin lymphoma for eradication of minimal residual disease in conjunction with autologous bone marrow transplantation (ABMT). Blood 1993; 82 (Suppl 1): 171a.
65. Slavin S, Naparstek E, Nagler A et al. Cell mediated immunotherapy (CMI) for the treatment of malignant hematological diseases in conjunction with autologous bone marrow transplantation (ABMT) Blood 1993; 82 (Suppl 1): 292a.
66. Slavin S, Nagler A, Naparstek E et al. Immunotherapy of leukemia in conjunction with non-myeloablative conditioning: Engraftment of blood stem cells and eradication of host leukemia with non-myeloablative conditioning based on fludarabine and anti-thymocyte globulin (ATG). Blood 1996; 88 (10): 614A.
67. Slavin S, Nagler A, Naparstek E et al. Non myeloablative conditioning in preparation for allogeneic stem cell transplantation: The future treatment of choice of hematologic malignancies and genetic diseases. Exp Hematol 1997; 25 (8): 787.
68. Slavin S, Nagler A, Naparstek E et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998; 91: 756-63.
69. Nagler A, Or R, Naparstek E et al. Secondary allogeneic peripheral blood stem cell transplantation (alloPBSCT) using a non-mycloablative conditioning reigmen for malignant lymphoma (ML) patients who relapsed after autologous bone marrow transplantation (ABMT). Blood 1997; 90: 550a.
70. Giralt S, Estev E, van Beisen K et al. Engraftment of allogeneic (allo) stem cells with purine analog conditioning non-myeloablative reigmens for induction of graft vs. leukemia. Exp Hematol 1996; 24: 2046.
71. Khouri I, Keating MJ, Andersson B et al. Fludarabine (FAMP) - based chemotherapy at conventional doses allows engraftment of allogeneic (allo) peripheral blood progenitor cell (PBSC) transplantation in chronic lymphocytic leukemia (CLL). Exp Hematol 1996; 24: 2046 (Abstr 126).